基于生存曲线和全身免疫炎症指数观察紫杉醇联合卡铂治疗老年卵巢癌的疗效

Efficacy of paclitaxel combined with carboplatin in the treatment of ovarian cancer in elderly patients based on survival curve and systemic immune inflammatory index

目的 研究生存曲线和全身免疫炎症(systemic immune-inflammation index,SII)指数评价紫杉醇联合卡铂对老年卵巢癌的治疗效果。方法 选取2003年1月—2021年1月于东南大学附属中大医院溧水分院就诊的老年卵巢癌患者60例,使用数字表法随机分为观察组和对照组,每组30例。对照组使用紫杉醇联合顺铂化疗,观察组使用紫杉醇联合卡铂化疗。观察并比较2组肿瘤标志物(CA125、CEA和CA199)水平、SII指数、临床疗效及生存周期。结果 治疗前,2组CEA、CA125和CA199水平差异均无统计学意义(P>0.05);治疗1个疗程和治疗2个疗程,2组CEA、CA125和CA199水平均明显低于同组治疗前(P<0.05),且2组治疗2疗程CEA、CA125和CA199水平均明显低于同组治疗1个疗程(P<0.05),而观察组CEA、CA125和CA199水平均显著低于对照组(P<0.05)。治疗前,2组SII指数比较,差异无统计学意义(P>0.05)。治疗1个疗程和治疗2个疗程,2组SII指数均小于同组治疗前(P<0.05),且2组治疗2个疗程SII指数明显小于同组治疗1个疗程(P<0.05),而观察组SII指数均明显低于对照组(P<0.05)。观察组疗效明显高于对照组(P<0.05)。治疗后,观察组无进展生存期、总生存期和12个月生存率均高于对照组(P<0.05)。观察组化疗不良反应发生率低于对照组,但差异无统计学意义(P>0.05)。结论 紫杉醇联合卡铂治疗老年卵巢癌患者,可改变SII指标值,抑制肿瘤进一步恶化,延长患者生存周期,治疗效果较为理想。

Objective To evaluate the curative effect of paclitaxel combined with carboplatin on ovarian cancer in elderly patients by survival curve and systemic immune inflammation index(SII).Methods A total of 60 elderly patients with ovarian cancer who were treated in Lishui Hospital of Zhongda Hospital Affiliated to Southeast University from January 2003 to January 2021 were selected and divided into observation group and control group by random number table method,with 30 cases in each group.The control group was treated with paclitaxel combined with cisplatin,and the observation group was treated with paclitaxel combined with carboplatin.The levels of tumor markers(CA125,CEA and CA199),SII index,clinical efficacy and survival cycle were observed and compared between the two groups.Results Before treatment,there was no significant difference in the levels of CEA,CA125 and CA199 between both groups(P>0.05).After one and two courses of treatment,the levels of CEA,CA125 and CA199 of both groups were significantly lower than those of the same group before treatment(P<0.05),and the levels of CEA,CA125 and CA199 of both groups after two courses of treatment were significantly lower than those of the same group after one course of treatment(P<0.05),while the levels of CEA,CA125 and CA199 of the observation group were significantly lower than those of the control group(P<0.05).Before treatment,there was no significant difference in SII index between both groups(P>0.05).After one and two courses of treatment,the SII index of both groups was significantly lower than that of the same group before treatment(P<0.05),and the SII index of both groups after two courses of treatment was significantly lower than that of the same group after one course of treatment(P<0.05),while the SII index of the observation group was significantly lower than that of the control group(P<0.05).The curative effect of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the progression-free survival,overall survival and 12-month survival rates of the observation group were higher than those of the control group(P<0.05).The incidence of adverse reactions of chemotherapy in the observation group was lower than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Paclitaxel combined with carboplatin in the treatment of elderly patients with ovarian cancer can change the SII index value,inhibit the further deterioration of the tumor,prolong the life cycle of the patients,and the treatment effect is ideal.